American hematologist-oncologist and health researcher, FDA official
Moderna’s mFlusiva has secured an advisory committee vote in favor of approval for adults 50 and older. The decision follows earlier FDA scrutiny and a high-profile dispute over study design, with the committee citing robust efficacy and a solid safety profile.